Clinical breakthroughs in EGFR inhibition: applying the science to your clinical practice.
Morse
Linda
L
Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002450:Cell Communication; D000068818:Cetuximab; D016903:Drug Monitoring / Q000451:nursing; D066246:ErbB Receptors / Q000037:antagonists & inhibitors* / Q000502:physiology; D000069347:Erlotinib Hydrochloride; D019317:Evidence-Based Medicine; D005544:Forecasting; D000077156:Gefitinib; D006801:Humans; D009369:Neoplasms / Q000628:therapy; D024802:Nurse's Role; D009730:Nursing Assessment; D009859:Oncology Nursing / Q000458:organization & administration*; D010347:Patient Care Planning; D047428:Protein Kinase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D011799:Quinazolines / Q000627:therapeutic use; D015398:Signal Transduction
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; D066246:ErbB Receptors; D000068818:Cetuximab; D000077156:Gefitinib